Optimum chemotherapy for the management of advanced biliary tract cancer

Table 1 Single-agent targeted therapies in phase II trials for advanced biliary tract cancer

Ref.	Line	N	Target	Treatment	RR (%)	PFS	OS
Philip et al[12] 2006	1-2	42	EGFR	Erlotinib	8	2.6	7.5
Costello et al[13] 2009	1-3	20	Proteasome	Bortezomib	0	1.5	9.5
Ramanathan et al[14] 2009	1-2	17	EGFR, HER2	Lapatinib	0	1.8	5.2
Buzzoni et al[15] 2010	2	18	mTOR	Everolimus	6	NA	NA
Bengala et al[16] 2010	1-5	46	VEGF, BRAF	Sorafenib	2	2.3	4.4
El Khoueiry et al[17] 2011	1	31	VEGF, BRAF	Sorafenib	0	3.0	9.0
Bekaii-Saab et al[18] 2011	1-2	28	MEK1-2	Selumetinib	12	3.7	9.8
Yi et al[19] 2012	2	56	VEGF	Sunitinib	8.9	1.7	NA

N: Number of participants; NA: Not available; OS: Overall survival; PFS: Progression-free survival; RR: Response rate.